targeted therapy

2023 ASCO Annual Meeting; #ASCO23
June 5, 2023 · ASCO Staff
The ASCO Annual Meeting is being held June 2 to 6. Research highlights from the day include using trastuzumab deruxtecan to treat HER2-expressing tumors and using CAR T-cell therapy to slow or stop multiple myeloma. Read More >>
2023 ASCO Annual Meeting; #ASCO23
June 4, 2023 · ASCO Staff
The ASCO Annual Meeting is being held June 2 to 6. Several notable studies will be presented today. Topics include radiation therapy in rectal cancer, osimertinib for lung cancer, vorasidenib for grade 2 glioma, nivolumab for Hodgkin lymphoma, and mirvetuximab soravtansine for ovarian cancer. Read More >>
2023 ASCO Annual Meeting; #ASCO23
June 3, 2023 · ASCO Staff
The ASCO Annual Meeting is being held June 2 to 6. A study that will be presented today explores combining immunotherapy and targeted therapy to reduce the risk of death and recurrence for people with advanced ovarian cancer. Read More >>
2023 ASCO Annual Meeting; #ASCO23
June 2, 2023 · ASCO Staff
The ASCO Annual Meeting is being held June 2 to 6, and here is some of the notable research that will be presented today. This research explores using less extensive surgery for cervical cancer and using targeted therapy to reduce the risk of breast cancer recurrence. Read More >>
ASCO ® Plenary Series
April 19, 2023 · Greg Guthrie, ASCO staff
Read about 2 studies from the April 2023 ASCO Plenary Series, which highlights the use of adagrasib to target several solid tumors with a KRAS G12C mutation and the use of toripalimab to treat stage III non-small cell lung cancer before and after surgery. Read More >>

Pages